Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:42:21 ON 01 NOV 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 08:42:32 ON 01 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 OCT 2007 HIGHEST RN 952091-02-0
DICTIONARY FILE UPDATES: 30 OCT 2007 HIGHEST RN 952091-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10563361a.str





chain nodes :
6 7 8 16 17 21 22 23
ring nodes :
1 2 3 4 5 10 11 12 13 14 15 26 27 28 29 30 31
chain bonds :
1-6 5-8 6-7 6-26 8-10 13-16 16-17 17-21 21-22 22-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15 26-27 26-31
27-28 28-29 29-30 30-31
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 5-8 6-7 6-26 8-10 10-11 10-15 11-12 12-13
13-14 13-16 14-15 16-17 17-21 21-22 22-23
normalized bonds :
26-27 26-31 27-28 28-29 29-30 30-31
isolated ring systems :
containing 1 : 26 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 21:CLASS 22:CLASS
23:CLASS 26:Atom 27:Atom 28:Atom 29:Atom 30:Atom 31:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 08:43:00 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 633 TO ITERATE

100.0% PROCESSED 633 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 11151 TO 14169
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 08:43:10 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 12901 TO ITERATE

100.0% PROCESSED 12901 ITERATIONS 49 ANSWERS
SEARCH TIME: 00.00.01

L3 49 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 08:43:14 ON 01 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Nov 2007 VOL 147 ISS 19
FILE LAST UPDATED: 31 Oct 2007 (20071031/ED)

=> s l3 full
L4 3 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:700231 CAPLUS
DOCUMENT NUMBER: 145:167259
TITLE: Preparation of heterocyclic derivatives as PPAR α and PPAR γ agonists
INVENTOR(S): Takahashi, Yoko; Nagata, Ryu; Ushiroda, Kantaro
PATENT ASSIGNEE(S): Dainippon Sumitomo Pharma Co., Ltd., Japan
SOURCE: PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006075638	A1	20060720	WO 2006-JP300248	20060112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1837329	A1	20070926	EP 2006-702664	20060112
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: JP 2005-6950 A 20050114
WO 2006-JP300248 W 20060112

OTHER SOURCE(S): MARPAT 145:167259
GI



I

AB The title compds. I [the ring Z is an optionally substituted heteroaryl; W4 is a single bond, lower alkylene, lower alkenylene, etc., Ar2 is an optionally substituted aryl, optionally substituted heteroaryl; W3 is a single bond, lower alkylene, lower alkenylene, etc.; Ar1 is an optionally substituted arylene, optionally substituted heteroarylene; each of W1 and W2 is an optionally substituted lower alkylene, optionally substituted lower alkenylene; and R1 is carboxyl, an alkoxycarbonyl, optionally substituted carbamoyl, etc.] are prepared Thus, 2-methyl-2-[(4-((1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl)benzyl)oxy]propionic acid was prepared in a multistep process starting from 1-benzenesulfonyl-1H-pyrrole and p-toluoyl chloride. The PPAR α and PPAR γ agonist activities of compds. of this invention at 10μM were demonstrated.

IT 900181-73-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic derivs. as PPAR α and PPAR γ agonists)

RN 900181-73-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 900181-74-0P 900181-75-1P 900181-76-2P
900182-62-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic derivs. as PPAR α and PPAR γ agonists)

RN 900181-74-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 900181-75-1 CAPLUS
CN Propanoic acid, 2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 900181-76-2 CAPLUS
CN Benzoic acid, 4-[[1-[(2Z)-3-[4-[(2-ethoxy-1-methyl-2-oxoethoxy)methyl]phenyl]-2-propenyl]-1H-pyrrol-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 900182-62-9 CAPLUS
CN Propanoic acid, 2-[[(2E)-3-[4-[[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]methyl]phenyl]-2-propenyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 900183-62-2P 900183-69-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic derivs. as PPAR α and PPAR γ agonists)
RN 900183-62-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 900183-69-9 CAPLUS
CN Morpholine, 4-[(2R)-2-[[(2E)-3-[4-[[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]methyl]phenyl]-2-propenyl]oxy]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:677588 CAPLUS

DOCUMENT NUMBER: 145:124570
TITLE: Preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole derivatives and related compounds for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome
INVENTOR(S): Nagano, Tomokazu
PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 181 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006182668	A	20060713	JP 2004-375862	20041227

PRIORITY APPLN. INFO.: JP 2004-375862 20041227
OTHER SOURCE(S): MARPAT 145:124570
GI



I



II

AB The title compds. [e.g. I; Zb = (un)substituted pyrrole, pyrazole, imidazole, triazole, indole, indazole, or benzimidazole; W2b = a single bond, SO, SO2, (un)substituted CONH or SO2NH, (un)substituted C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene optionally two H atoms of methylene group substituted with O to form a CO group; Ar1b, Ar2b = (un)substituted aryl or heteroaryl; W1b = (un)substituted C1-5 alkylene, C2-5 alkenylene, or C2-5 alkynylene, -Yb-W3b- (Yb = O, S, (un)substituted NH; W3b = (un)substituted C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene), etc.; X1b = SO2, OCO2, SO2O, (un)substituted CONHSO2, NHSO2, NHCO, SO2NHCO, SO2NH, CONH, OCONH, NHCONH, or NHC(NH2):N-, etc.; R1b = CO2H, alkoxycarbonyl, (un)substituted CONH2, cyclic aminocarbonyl, alkylsulfonylcarbamoyl, arylsulfonylcarbonyl, or heteroarylsulfonylcarbonyl, tetrazolyl, 2,4-dioxooxazolidin-5-yl, etc.] are prepared These compds. are agonists (activators) of PPARα and/or PPARγ and not only improve hyperglycemia but also possess lipid improving activity such as improving hypertriglyceridemia and increasing HDL cholesterol. They are useful for the treatment or prevention of hyperlipidemia, arteriosclerosis, and/or the metabolic syndrome. For example, compound (II).Na activated human PPARα and human PPARγ by 15.1 and 7.0%, resp., at 10 μM. When it was administered to mice at 30 mg/kg for 2 wk p.o., it lowered blood sugar and triglyceride by 70 and

89%, resp., and increased HDL by 41%.

IT 840503-43-7P, (2R)-3-Hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester
840503-44-8P, (2R)-2-Hydroxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid ethyl ester
897939-51-4P, (2R)-3-[(tert-Butyldimethylsilyl)oxy]-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole derivs. and related compds. for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome)

RN 840503-43-7 CAPLUS

CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-44-8 CAPLUS

CN Propanoic acid, 2-hydroxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 897939-51-4 CAPLUS

CN Propanoic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 840502-24-1P, 2-Methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-27-4P , (2R)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-29-6P, (2S)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-32-1P, (2S)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt 840502-33-2P, (2R)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt 840502-34-3P, (2R)-2-[[4-[3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]propyl]benzyl]oxy]propionic acid 840502-36-5P 840502-39-8P 840502-42-3P 840502-44-5P 840502-45-6P 840502-46-7P 840502-48-9P 840502-49-0P 840502-51-4P 840502-76-3P 840502-77-4P 840502-78-5P 840502-80-9P 840502-81-0P 840502-87-6P 840502-98-9P, 2-Methyl-2-[[4-[(1E)-2-methyl-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-99-0P 840503-00-6P, (2R)-2-Hydroxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840503-01-7P , (2R)-2-Methoxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840503-34-6P, 2-Methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester 840503-36-8P, (2R)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester 840503-38-0P, (2S)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester 897939-49-0P 897939-91-2P 897939-93-4P 897939-95-6P 897939-96-7P 897939-97-8P 897939-98-9P 897939-99-0P 897940-00-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole derivs. and related compds. for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome)

RN 840502-24-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-27-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-29-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-32-1 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-29-6
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-33-2 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-27-4
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-34-3 CAPLUS
CN Propanoic acid, 2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 840502-36-5 CAPLUS
CN Propanamide, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-N-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-39-8 CAPLUS
CN Butanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-42-3 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-44-5 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-45-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-46-7 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-48-9 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-49-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-51-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3,5-dimethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-76-3 CAPLUS
CN Propanoic acid, 2-[[6-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-3-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-77-4 CAPLUS
CN Propanoic acid, 2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-78-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-80-9 CAPLUS
CN Propanoic acid, 2-[1-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-81-0 CAPLUS
CN Butanoic acid, 3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-87-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]- (CA INDEX NAME)



RN 840502-98-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-2-methyl-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-99-0 CAPLUS
CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 840503-00-6 CAPLUS
CN Propanoic acid, 2-hydroxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-01-7 CAPLUS
CN Propanoic acid, 2-methoxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-34-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840503-36-8 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-38-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 897939-49-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[2-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 897939-91-2 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 897939-93-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 897939-95-6 CAPLUS
CN Propanoic acid, 2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 897939-96-7 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 897939-97-8 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 897939-98-9 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 897939-99-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● Na

RN 897940-00-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● Na

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:120880 CAPLUS
DOCUMENT NUMBER: 142:219144
TITLE: Preparation of benzoylpyrrole derivatives as PPAR agonist
INVENTOR(S): Watanabe, Ken-ichi; Maruta, Katsunori; Ushiroda, Kantaro; Nagata, Ryu
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012245	A1	20050210	WO 2004-JP10282	20040713

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2531064	A1	20050210	CA 2004-2531064		20040713
EP 1647546	A1	20060419	EP 2004-747746		20040713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
US 2006194857	A1	20060831	US 2004-563361		20040713
CN 1849303	A	20061018	CN 2004-80026235		20040713
IN 2006CN00142	A	20070629	IN 2006-CN142		20060112
MX 2006PA00539	A	20060330	MX 2006-PA539		20060113
PRIORITY APPLN. INFO.:			JP 2003-274684	A	20030715
			WO 2004-JP10282	W	20040713

OTHER SOURCE(S): MARPAT 142:219144

GI



I



II

AB Title compds. represented by the formula I [wherein ring Z = (un)substituted heteroaryl; R1 = carboxyl, alkoxycarbonyl, (un)substituted carbamoyl, etc.; W1, W2 = independently (un)substituted alkyl; Ar1 = (un)substituted (hetero)arylene; W3 = single bond, alkylene, alkenylene or Y1W5; Y1 = O, S, SO or SO2; W5 = alkylene or alkenylene; W4 = single bond, amino(alkylene), alkylene, alkenylene; Ar2 = (un)substituted (hetero)aryl; their prodrugs, and pharmaceutically acceptable salts thereof] were prepared as PPARα and PPARγ agonist. For example, II was given in a multi-step synthesis starting from Me 2-hydroxyisobutyrate. Selected I showed agonic activity of PPARα and PPARγ, and were tested for lowering blood sugar effect. Thus, I are useful as PPARα and PPARγ agonists for the treatment of diabetes.

IT 840502-24-1P 840502-27-4P 840502-29-6P
840502-32-1P 840502-33-2P 840502-34-3P
840502-36-5P 840502-39-8P 840502-42-3P
840502-44-5P 840502-45-6P 840502-46-7P
840502-48-9P 840502-49-0P 840502-51-4P
840502-76-3P 840502-77-4P 840502-78-5P
840502-79-6P 840502-80-9P 840502-81-0P
840502-87-6P 840502-98-9P 840502-99-0P
840503-00-6P 840503-01-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoylpyrrole derivs. as PPAR agonist for treatment of diabetes)

RN 840502-24-1 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-27-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-29-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-32-1 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-29-6
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-33-2 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-27-4
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-34-3 CAPLUS
CN Propanoic acid, 2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 840502-36-5 CAPLUS
CN Propanamide, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-N-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-39-8 CAPLUS
CN Butanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-42-3 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-44-5 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-45-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-46-7 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-48-9 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-49-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-51-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3,5-dimethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-76-3 CAPLUS
CN Propanoic acid, 2-[[6-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-3-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-77-4 CAPLUS
CN Propanoic acid, 2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-78-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-79-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[2-[6-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-3-pyridinyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-80-9 CAPLUS
CN Propanoic acid, 2-[1-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-81-0 CAPLUS
CN Butanoic acid, 3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-87-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]- (CA INDEX NAME)



RN 840502-98-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-2-methyl-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-99-0 CAPLUS
CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-00-6 CAPLUS
CN Propanoic acid, 2-hydroxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-01-7 CAPLUS
CN Propanoic acid, 2-methoxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 840503-34-6P 840503-36-8P 840503-38-0P
840503-42-6P 840503-43-7P 840503-44-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoylpyrrole derivs. as PPAR agonist for treatment of diabetes)
RN 840503-34-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840503-36-8 CAPLUS

CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-38-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-42-6 CAPLUS
CN Propanoic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-43-7 CAPLUS
CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-44-8 CAPLUS
CN Propanoic acid, 2-hydroxy-3-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, ethyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 08:42:21 ON 01 NOV 2007)

     FILE 'REGISTRY' ENTERED AT 08:42:32 ON 01 NOV 2007
L1             STRUCTURE UPLOADED
L2           2 S L1
L3          49 S L1 FULL

     FILE 'CAPLUS' ENTERED AT 08:43:14 ON 01 NOV 2007
L4           3 S L3 FULL

=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   17.22     189.53

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                   -2.34      -2.34

STN INTERNATIONAL LOGOFF AT 08:44:56 ON 01 NOV 2007
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUL 02	LMEDLINE coverage updated
NEWS 3	JUL 02	SCISEARCH enhanced with complete author names
NEWS 4	JUL 02	CHEMCATS accession numbers revised
NEWS 5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS 6	JUL 16	CAplus enhanced with French and German abstracts
NEWS 7	JUL 18	CA/CAplus patent coverage enhanced
NEWS 8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 9	JUL 30	USGENE now available on STN
NEWS 10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 15	AUG 27	USPATOLD now available on STN
NEWS 16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 18	SEP 13	FORIS renamed to SOFIS
NEWS 19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 24	OCT 19	BEILSTEIN updated with new compounds

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 06:08:36 ON 01 NOV 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'REGISTRY' ENTERED AT 06:09:31 ON 01 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 30 OCT 2007 HIGHEST RN 952091-02-0
DICTIONARY FILE UPDATES: 30 OCT 2007 HIGHEST RN 952091-02-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10563361.str





chain nodes :
6 7 8 16 17 21 22 23
ring nodes :
1 2 3 4 5 10 11 12 13 14 15 28 29 30 31 32 33
chain bonds :
1-6 5-8 6-7 6-28 8-10 13-16 16-17 17-21 21-22 22-23
ring bonds :
1-2 1-5 2-3 3-4 4-5 10-11 10-15 11-12 12-13 13-14 14-15 28-29 28-33
29-30 30-31 31-32 32-33
exact/norm bonds :
1-2 1-5 1-6 2-3 3-4 4-5 5-8 6-7 6-28 8-10 10-11 10-15 11-12 12-13
13-14 13-16 14-15 16-17 17-21 21-22 22-23
normalized bonds :
28-29 28-33 29-30 30-31 31-32 32-33
isolated ring systems :
containing 1 : 28 :

G1:C,O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 10:Atom 11:Atom
12:Atom 13:Atom 14:Atom 15:Atom 16:CLASS 17:CLASS 21:CLASS 22:CLASS
23:CLASS 28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 06:09:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 198 TO ITERATE

100.0% PROCESSED 198 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3116 TO 4804
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 06:10:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4023 TO ITERATE

100.0% PROCESSED 4023 ITERATIONS 53 ANSWERS
SEARCH TIME: 00.00.01

L3 53 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	172.10	172.52

FILE 'CAPLUS' ENTERED AT 06:10:09 ON 01 NOV 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 1 Nov 2007 VOL 147 ISS 19
FILE LAST UPDATED: 31 Oct 2007 (20071031/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3 full
L4 6 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:700231 CAPLUS
DOCUMENT NUMBER: 145:167259
TITLE: Preparation of heterocyclic derivatives as PPAR α and PPAR γ agonists
INVENTOR(S): Takahashi, Yoko; Nagata, Ryu; Ushiroda, Kantaro
PATENT ASSIGNEE(S): Dainippon Sumitomo Pharma Co., Ltd., Japan
SOURCE: PCT Int. Appl., 195 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006075638	A1	20060720	WO 2006-JP300248	20060112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1837329	A1	20070926	EP 2006-702664	20060112
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				

PRIORITY APPLN. INFO.: JP 2005-6950 A 20050114
WO 2006-JP300248 W 20060112

OTHER SOURCE(S): MARPAT 145:167259
GI



I

AB The title compds. I [the ring Z is an optionally substituted heteroaryl; W4 is a single bond, lower alkylene, lower alkenylene, etc., Ar2 is an optionally substituted aryl, optionally substituted heteroaryl; W3 is a single bond, lower alkylene, lower alkenylene, etc.; Ar1 is an optionally substituted arylene, optionally substituted heteroarylene; each of W1 and W2 is an optionally substituted lower alkylene, optionally substituted lower alkenylene; and R1 is carboxyl, an alkoxycarbonyl, optionally substituted carbamoyl, etc.] are prepared Thus, 2-methyl-2-[(4-((1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl)benzyl)oxy]propionic acid was prepared in a multistep process starting from 1-benzenesulfonyl-1H-pyrrole and p-toluoyl chloride. The PPAR α and PPAR γ agonist activities of compds. of this invention at 10μM were demonstrated.

IT 900181-73-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heterocyclic derivs. as PPAR α and PPAR γ agonists)

RN 900181-73-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 900181-74-0P 900181-75-1P 900181-76-2P
900182-62-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic derivs. as PPAR α and PPAR γ agonists)

RN 900181-74-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 900181-75-1 CAPLUS
CN Propanoic acid, 2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 900181-76-2 CAPLUS
CN Benzoic acid, 4-[[1-[(2Z)-3-[4-[(2-ethoxy-1-methyl-2-oxoethoxy)methyl]phenyl]-2-propenyl]-1H-pyrrol-2-yl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 900182-62-9 CAPLUS
CN Propanoic acid, 2-[[(2E)-3-[4-[[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]methyl]phenyl]-2-propenyl]oxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 900183-62-2P 900183-69-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic derivs. as PPAR α and PPAR γ agonists)
RN 900183-62-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1Z)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 900183-69-9 CAPLUS
CN Morpholine, 4-[(2R)-2-[[(2E)-3-[4-[[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]methyl]phenyl]-2-propenyl]oxy]-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:677588 CAPLUS
DOCUMENT NUMBER: 145:124570
TITLE: Preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole derivatives and related compounds for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome
INVENTOR(S): Nagano, Tomokazu
PATENT ASSIGNEE(S): Dainippon Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 181 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2006182668	A	20060713	JP 2004-375862	20041227
PRIORITY APPLN. INFO.:			JP 2004-375862	20041227
OTHER SOURCE(S):	MARPAT 145:124570			

GI



I



II

AB The title compds. [e.g. I; Zb = (un)substituted pyrrole, pyrazole, imidazole, triazole, indole, indazole, or benzimidazole; W2b = a single bond, SO, SO2, (un)substituted CONH or SO2NH, (un)substituted C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene optionally two H atoms of methylene group substituted with O to form a CO group; Ar1b, Ar2b = (un)substituted aryl or heteroaryl; W1b = (un)substituted C1-5 alkylene, C2-5 alkenylene, or C2-5 alkynylene, -Yb-W3b- (Yb = O, S, (un)substituted NH; W3b = (un)substituted C1-4 alkylene, C2-4 alkenylene, or C2-4 alkynylene), etc.; X1b = SO2, OCO2, SO2O, (un)substituted CONHSO2, NHSO2, NHCO, SO2NHCO, SO2NH, CONH, OCONH, NHCONH, or NHC(NH2):N-, etc.; R1b = CO2H, alkoxycarbonyl, (un)substituted CONH2, cyclic aminocarbonyl, alkylsulfonylcarbamoyl, arylsulfonylcarbonyl, or heteroarylsulfonylcarbonyl, tetrazolyl, 2,4-dioxooxazolidin-5-yl, etc.] are prepared These compds. are agonists (activators) of PPARα and/or PPARγ and not only improve hyperglycemia but also possess lipid improving activity such as improving hypertriglyceridemia and increasing HDL cholesterol. They are useful for the treatment or prevention of hyperlipidemia, arteriosclerosis, and/or the metabolic syndrome. For

example, compound (II).Na activated human PPARα and human PPARγ by 15.1 and 7.0%, resp., at 10 μM. When it was administered to mice at 30 mg/kg for 2 wk p.o., it lowered blood sugar and triglyceride by 70 and 89%, resp., and increased HDL by 41%.

IT 840503-43-7P, (2R)-3-Hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester
897939-51-4P, (2R)-3-[(tert-Butyldimethylsilyl)oxy]-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole derivs. and related compds. for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome)

RN 840503-43-7 CAPLUS

CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 897939-51-4 CAPLUS

CN Propanoic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 840502-24-1P, 2-Methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-

pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-27-4P , (2R)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-29-6P, (2S)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-32-1P, (2S)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt 840502-33-2P, (2R)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt 840502-34-3P, (2R)-2-[[4-[3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]propyl]benzyl]oxy]propionic acid 840502-36-5P 840502-39-8P 840502-42-3P 840502-44-5P 840502-45-6P 840502-46-7P 840502-48-9P 840502-49-0P 840502-51-4P 840502-76-3P 840502-77-4P 840502-78-5P 840502-80-9P 840502-87-6P 840502-98-9P, 2-Methyl-2-[[4-[(1E)-2-methyl-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid 840502-99-0P 840503-34-6P, 2-Methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester 840503-36-8P, (2R)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester 840503-38-0P, (2S)-2-[[4-[(1E)-3-[2-(4-Methylbenzoyl)-1H-pyrrol-1-yl]prop-1-en-1-yl]benzyl]oxy]propionic acid methyl ester 897939-49-0P 897939-91-2P 897939-93-4P 897939-95-6P 897939-96-7P 897939-97-8P 897939-98-9P 897939-99-0P 897940-00-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 2-benzoylpyrrole, 2-benzoylimidazole, 2-benzoylbenzimidazole derivs. and related compds. for treatment or prevention of hyperlipidemia, arteriosclerosis, and/or metabolic syndrome)

RN 840502-24-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-27-4 CAPLUS

CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 840502-29-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-32-1 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-29-6
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-33-2 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-27-4
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-34-3 CAPLUS
CN Propanoic acid, 2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 840502-36-5 CAPLUS
CN Propanamide, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-N-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-39-8 CAPLUS
CN Butanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-42-3 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-44-5 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-45-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-46-7 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-48-9 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-49-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-51-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3,5-dimethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-76-3 CAPLUS
CN Propanoic acid, 2-[[6-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-3-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-77-4 CAPLUS
CN Propanoic acid, 2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-

propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-78-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-80-9 CAPLUS
CN Propanoic acid, 2-[1-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-87-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]- (CA INDEX NAME)



RN 840502-98-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-2-methyl-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-99-0 CAPLUS
CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-34-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840503-36-8 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-38-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 897939-49-0 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 897939-91-2 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 897939-93-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● Na

RN 897939-95-6 CAPLUS
CN Propanoic acid, 2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

RN 897939-96-7 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 897939-97-8 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 897939-98-9 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl-, sodium salt (9CI) (CA INDEX NAME)

Double bond geometry as shown.



● Na

RN 897939-99-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● Na

RN 897940-00-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, sodium salt, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2005:120880 CAPLUS
DOCUMENT NUMBER: 142:219144
TITLE: Preparation of benzoylpyrrole derivatives as PPAR agonist
INVENTOR(S): Watanabe, Ken-ichi; Maruta, Katsunori; Ushiroda, Kantaro; Nagata, Ryu
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012245	A1	20050210	WO 2004-JP10282	20040713
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2531064	A1	20050210	CA 2004-2531064	20040713
EP 1647546	A1	20060419	EP 2004-747746	20040713
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 2006194857	A1	20060831	US 2004-563361	20040713
CN 1849303	A	20061018	CN 2004-80026235	20040713
IN 2006CN00142	A	20070629	IN 2006-CN142	20060112
MX 2006PA00539	A	20060330	MX 2006-PA539	20060113
PRIORITY APPLN. INFO.:			JP 2003-274684 A	20030715
			WO 2004-JP10282 W	20040713

OTHER SOURCE(S): MARPAT 142:219144
GI



I



II

AB Title compds. represented by the formula I [wherein ring Z = (un)substituted heteroaryl; R1 = carboxyl, alkoxycarbonyl, (un)substituted carbamoyl, etc.; W1, W2 = independently (un)substituted alkyl; Ar1 = (un)substituted (hetero)arylene; W3 = single bond, alkylene, alkenylene or Y1W5; Y1 = O, S, SO or SO2; W5 = alkylene or alkenylene; W4 = single bond, amino(alkylene), alkylene, alkenylene; Ar2 = (un)substituted (hetero)aryl; their prodrugs, and pharmaceutically acceptable salts thereof] were prepared as PPARα and PPARγ agonist. For example, II was given in a multi-step synthesis starting from Me 2-hydroxyisobutyrate. Selected I showed agonic activity of PPARα and PPARγ, and were tested for lowering blood sugar effect. Thus, I are useful as PPARα and PPARγ agonists for the treatment of diabetes.

IT 840502-24-1P 840502-27-4P 840502-29-6P
840502-32-1P 840502-33-2P 840502-34-3P
840502-36-5P 840502-39-8P 840502-42-3P
840502-44-5P 840502-45-6P 840502-46-7P
840502-48-9P 840502-49-0P 840502-51-4P
840502-76-3P 840502-77-4P 840502-78-5P
840502-79-6P 840502-80-9P 840502-87-6P
840502-98-9P 840502-99-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzoylpyrrole derivs. as PPAR agonist for treatment of diabetes)

RN 840502-24-1 CAPLUS

CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-27-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-29-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-32-1 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2S)-, compd. with 2-amino-2-(hydroxymethyl)-

1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-29-6
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-33-2 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 840502-27-4
CMF C25 H25 N O4

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 77-86-1
CMF C4 H11 N O3



RN 840502-34-3 CAPLUS
CN Propanoic acid, 2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 840502-36-5 CAPLUS
CN Propanamide, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-N-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-39-8 CAPLUS
CN Butanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-42-3 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-44-5 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840502-45-6 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-46-7 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-ethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-48-9 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-49-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-51-4 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(3,5-dimethylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-2-methyl- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-76-3 CAPLUS
CN Propanoic acid, 2-[[6-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-

propenyl]-3-pyridinyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-77-4 CAPLUS
CN Propanoic acid, 2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-78-5 CAPLUS
CN Propanoic acid, 2-methyl-2-[[5-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-2-thienyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-79-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[2-[6-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]-3-pyridinyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-80-9 CAPLUS
CN Propanoic acid, 2-[1-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]ethoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-87-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]propyl]phenyl]methoxy]- (CA INDEX NAME)



RN 840502-98-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-2-methyl-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840502-99-0 CAPLUS
CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



IT 840503-34-6P 840503-36-8P 840503-38-0P
840503-42-6P 840503-43-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzoylpyrrole derivs. as PPAR agonist for treatment of diabetes)
RN 840503-34-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 840503-36-8 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-38-0 CAPLUS
CN Propanoic acid, 2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-42-6 CAPLUS
CN Propanoic acid, 3-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl

ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 840503-43-7 CAPLUS
CN Propanoic acid, 3-hydroxy-2-[[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenyl]methoxy]-, methyl ester, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:811768 CAPLUS
DOCUMENT NUMBER: 139:302057
TITLE: Pyrrole derivatives as PPAR activators and hypolipidemics
INVENTOR(S): Tsuchida, Atsushi; Yasuchi, Mutsuo; Maruta, Katsunori; Iwai, Kiyotaka; Kito, Makoto; Nagata, Ryu
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 69 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003292439	A	20031015	JP 2002-168110	20020610

PRIORITY APPLN. INFO.: JP 2002-26824 A 20020204
OTHER SOURCE(S): MARPAT 139:302057

AB Pyrrole derivs. (Markush's structures given) are claimed as PPAR-α and -γ activators and hypolipidemics.

IT 474006-64-9P 474006-65-0P 474006-68-3P
474006-69-4P 474006-83-2P 474007-43-7P
474007-45-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrrole derivs. as PPAR activators and hypolipidemics)

RN 474006-64-9 CAPLUS
CN Acetic acid, [4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-65-0 CAPLUS
CN Acetic acid, [4-[(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-68-3 CAPLUS
CN Acetic acid, [4-[(1E)-4-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-butenyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-69-4 CAPLUS
CN Acetic acid, [4-[(1E)-4-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-83-2 CAPLUS
CN Acetic acid, [4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propynyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 474007-43-7 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474007-45-9 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[2-[4-(1-methylethyl)benzoyl]-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:671033 CAPLUS
DOCUMENT NUMBER: 139:191450
TITLE: Pyrrole derivatives as liver glyconeogenesis inhibitors

INVENTOR(S): Nagata, Ryu; Kito, Makoto; Itakura, Yasushi
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 73 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003238403	A	20030827	JP 2002-32125	20020208
PRIORITY APPLN. INFO.:			JP 2002-32125	20020208

OTHER SOURCE(S): MARPAT 139:191450

AB Pyrrole derivs. (Markush's structures given) are claimed as liver glyconeogenesis inhibitors for treatment of diabetes and complications. The pyrrole derivs. were prepared, and their antidiabetic effects were tested.

IT 474006-64-9P 474006-65-0P 474006-68-3P
474006-69-4P 474007-43-7P 474007-45-9P
585526-80-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pyrrole derivs. as liver glyconeogenesis inhibitors and antidiabetics)

RN 474006-64-9 CAPLUS
CN Acetic acid, [4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-65-0 CAPLUS
CN Acetic acid, [4-[(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-68-3 CAPLUS
CN Acetic acid, [4-[(1E)-4-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-butenyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-69-4 CAPLUS
CN Acetic acid, [4-[(1E)-4-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474007-43-7 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474007-45-9 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[2-[4-(1-methylethyl)benzoyl]-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 585526-80-3 CAPLUS
CN Acetic acid, [4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propynyl]phenoxy]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2002:832756 CAPLUS
DOCUMENT NUMBER: 137:337775
TITLE: Preparation of pyrrole derivatives having antidiabetic activity
INVENTOR(S): Nagata, Ryu; Maruta, Katsunori; Iwai, Kiyotaka; Kitoh, Makoto; Ushiroda, Kantaro; Yoshida, Kozo
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Japan
SOURCE: PCT Int. Appl., 248 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002085851	A1	20021031	WO 2002-JP3790	20020417
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002251462	A1	20021105	AU 2002-251462	20020417
EP 1386913	A1	20040204	EP 2002-720442	20020417
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2004162331	A1	20040819	US 2003-474943	20031016
US 7220773	B2	20070522		
PRIORITY APPLN. INFO.:			JP 2001-120887 A	20010419
			WO 2002-JP3790 W	20020417

OTHER SOURCE(S): MARPAT 137:337775
GI



I





AB Novel pyrrole derivs. represented by the following formula (I) and salts thereof [R1 = Q, W12-X12-Ar1, Q1, etc. {wherein X11 = a single bond, O, S; W11 = each (un)substituted C2-5 alkylene, alkenylene, or alkynylene; one of Z1 and Z2 = a C atom substituted by X1-Y1-COR6 (wherein X1 = a single bond, O, S; Y1 = each (un)substituted C1-4 alkylene, C2-5 alkenylene, or C2-5 alkynylene; R6 = HO, each (un)substituted C1-4 alkoxy, C1-4 alkylsulfonylamino, or phenylsulfonylamino) and the other = H, HO, halo, cyano, CONH2, C2-5 alkylaminocarbonyl, etc.; Z3, Z4, Z5 = (un)substituted CH; Ar1 = substituted naphthyl; X12 = a single bond, O, S; W12 = (un)substituted C1-4 alkylene; X13 = a single bond, O, S; W13 = (un)substituted C1-4 alkylene; one of R8 and R9 = X3-Y3-COR11 (wherein X3 = a single bond, O, S; Y3 = (un)substituted C1-4 alkylene, C2-5 alkenylene, or C2-5 alkynylene; R11 = HO, (un)substituted C1-4 alkoxy,

C1-4 alkylsulfonylamino, or phenylsulfonylamino) and the other = H, HO, (un)substituted C1-4 alkyl, C2-5 alkenyl, C2-5 alkynyl, C1-4 alkoxy, etc.}; one of R2 and R3 = W21-A21 (wherein W21 = (un)substituted C1-6 alkylene, (un)substituted alkenylene, CONH, or CONHCH2; A21 = (un)substituted C6-12 aryl or mono- or dicyclic unsatd. heterocyclyl containing same or different 1-3 heteroatoms selected from N, O, and S) and the other = H, (un)substituted C1-4 alkyl, halo; R4, R5 = H, (un)substituted C1-4 alkyl, halo] are prepared These compds. improve insulin resistance and high blood sugar, have antidiabetic activity, and safely control blood sugar. Thus, a solution of 240 mg 2-(4-methylbenzoyl)pyrrole (preparation given) in 2.0 mL THF was added to a solution of 160 mg potassium tert-butoxide in THF 3.0 mL, stirred at room temperature for 20 min, and ice-cooled followed by adding a solution of 370 mg Me [3-[(1E)-3-bromo-1-propenyl]phenoxy]acetate in 4.0 mL THF, and the resulting mixture was stirred at room temperature for 1.5 h to give 31% Me [3-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]acetate (II). A solution of II in 1 N aqueous LiOH 1.0, THF 1.0, and MeOH 1.0 mL was stirred at room temperature for 30 min, treated with dilute aqueous HCl, and extracted with EtOAc to give 100% [3-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]acetic acid (III). When male db/db mice were fed with a feed containing 0.1% III for 2 wk, the blood sugar was lowered by 70%.

IT 474006-64-9P 474006-65-0P 474006-68-3P
474006-69-4P 474006-83-2P 474007-43-7P
474007-45-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrole derivs. as antidiabetics for improving insulin resistance and lowering blood sugar)

RN 474006-64-9 CAPLUS
CN Acetic acid, [4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-65-0 CAPLUS
CN Acetic acid, [4-[(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-68-3 CAPLUS
CN Acetic acid, [4-[(1E)-4-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-butenyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-69-4 CAPLUS
CN Acetic acid, [4-[(1E)-4-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-butenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474006-83-2 CAPLUS
CN Acetic acid, [4-[3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propynyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



RN 474007-43-7 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[2-(4-methylbenzoyl)-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 474007-45-9 CAPLUS
CN Propanoic acid, 2-[4-[(1E)-3-[2-[4-(1-methylethyl)benzoyl]-1H-pyrrol-1-yl]-1-propenyl]phenoxy]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 06:08:36 ON 01 NOV 2007)

FILE 'REGISTRY' ENTERED AT 06:09:31 ON 01 NOV 2007
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 53 S L1 FULL

FILE 'CAPLUS' ENTERED AT 06:10:09 ON 01 NOV 2007
L4 6 S L3 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	33.97	206.49
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-4.68	-4.68

STN INTERNATIONAL LOGOFF AT 06:13:06 ON 01 NOV 2007